Mitochondrial dysfunction in human hypertrophic cardiomyopathy is linked to cardiomyocyte architecture disruption and corrected by improving NADH-driven mitochondrial respiration
European Heart Journal

Abstract
Genetic hypertrophic cardiomyopathy (HCM) is caused by mutations in sarcomere protein-encoding genes (i.e. genotype-positive HCM). In an increasing number of patients, HCM occurs in the absence of a mutation (i.e. genotype-negative HCM). Mitochondrial dysfunction is thought to be a key driver of pathological remodelling in HCM. Reports of mitochondrial respiratory function and specific disease-modifying treatment options in patients with HCM are scarce.
Respirometry was performed on septal myectomy tissue from patients with HCM (
Mitochondrial dysfunction is explained by cardiomyocyte architecture disruption and is linked to septal hypertrophy in genotype-negative HCM. Despite severe myocardial remodelling mitochondria were responsive to treatments aimed at restoring respiratory function, eliciting the mitochondria as a drug target to prevent and ameliorate cardiac disease in HCM. Mitochondria-targeting therapy may particularly benefit genotype-negative patients with HCM, given the tight link between mitochondrial impairment and septal thickening in this subpopulation.
Contributors

Edgar E Nollet
Author

Inez Duursma
Author

Anastasiya Rozenbaum
Author

Moritz Eggelbusch
Author

Rob C I Wüst
Author

Michelle Michels
Author

Mark Jansen
Author

Nicole N van der Wel
Author

Kenneth C Bedi
Author

Kenneth B Margulies
Author

Jeff Nirschl
Author

Jolanda van der Velden
Author
Amsterdam University Medical Centre (AUMC) Amsterdam , Netherlands (The)
You may be interested in




